STOCK TITAN

Pacira BioSciences to Participate in Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Pacira BioSciences (Nasdaq: PCRX), a leading provider of non-opioid pain therapies, has announced its participation in the 24th Annual Needham Virtual Healthcare Conference. The company will engage in an analyst-led fireside chat scheduled for Monday, April 7, 2025, at 11:45 AM ET.

Interested parties can access the live audio stream of the virtual event through the 'Events' section on the company's investor website at investor.pacira.com. A recording of the webcast will remain available for two weeks after the event.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

-3.14% News Effect

On the day this news was published, PCRX declined 3.14%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

BRISBANE, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 24th Annual Needham Virtual Healthcare Conference at 11:45 AM ET on Monday, April 7, 2025.

Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

About Pacira

Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing the development of PCRX-201, a novel locally administered gene therapy with the potential to treat large prevalent diseases like osteoarthritis. To learn more about Pacira, visit www.pacira.com.



Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com

FAQ

When is Pacira BioSciences (PCRX) presenting at the Needham Healthcare Conference 2025?

Pacira BioSciences will present on Monday, April 7, 2025, at 11:45 AM ET during the 24th Annual Needham Virtual Healthcare Conference.

How can investors access PCRX's Needham Conference presentation?

Investors can access the live audio stream through the 'Events' page at investor.pacira.com, with replay available for two weeks post-event.

What is the format of PCRX's presentation at the Needham Healthcare Conference?

The presentation will be in the format of an analyst-led fireside chat discussion.

How long will PCRX's Needham Conference presentation recording be available?

The webcast recording will be available for replay for two weeks following the April 7, 2025 event.
Pacira Biosciences Inc

NASDAQ:PCRX

PCRX Rankings

PCRX Latest News

PCRX Latest SEC Filings

PCRX Stock Data

1.12B
42.21M
1.81%
115.93%
14.71%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
BRISBANE